Hims rises as FDA considers broader peptides access; analysts see long-term win

Hims & Hers Health shares rose more than 7% after analysts said the FDA's consideration of allowing compounding pharmacies to manufacture popular peptides could support the telehealth company over the long run. The move reflects a potentially favorable regulatory backdrop for a core treatment area, though the news is still exploratory rather than a finalized policy change.

Analysis

Hims & Hers Health shares rose more than 7% after analysts said the FDA's consideration of allowing compounding pharmacies to manufacture popular peptides could support the telehealth company over the long run. The move reflects a potentially favorable regulatory backdrop for a core treatment area, though the news is still exploratory rather than a finalized policy change.